news8 March 2023 | By Catherine Eckford (European Pharmaceutical Review)
Adaptimmune Therapeutics and TCR² Therapeutics’ new cell therapy company could gain the first approval for an engineered T-cell receptor (TCR) T-cell therapy for a solid tumour.